Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS
6. AZN
7. NVS
8. ROIV
9. ORCL
10. AAPL

Go back to Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
(NASDAQ: MDCX) Delayed: 0.17 --0 (-0%)
Previous Close $0.17    52 Week High $ 
Open $0.17    52 Week Low $ 
Day High $0.20    P/E N/A 
Day Low $0.16    EPS $ 
Volume 23,223,137       

(NASDAQ: MDCX) Delayed: 0.17 --0 (-0%)
Previous Close $0.17    52 Week High $ 
Open $0.17    52 Week Low $ 
Day High $0.20    P/E N/A 
Day Low $0.16    EPS $ 
Volume 23,223,137